Cosmos Health Inc. is a diversified, vertically integrated global healthcare company. The Company owns a portfolio of proprietary pharmaceutical and nutraceutical brands, including Sky Premium Life, Mediterranation, bio-bebe, C-Sept and C-Scrub. Through its subsidiary Cana Laboratories S.A., it manufactures pharmaceuticals, food supplements, cosmetics, biocides, and medical devices within the European Union. It also distributes a broad line of pharmaceuticals and parapharmaceuticals, including branded generics and over-the-counter (OTC) medications, to retail pharmacies and wholesale distributors through its subsidiaries in Greece and the United Kingdom. It also has research and development (R&D) partnerships targeting health disorders such as obesity, diabetes, and cancer, enhanced by artificial intelligence drug repurposing technologies, and focuses on the R&D of patented nutraceuticals, specialized root extracts, proprietary complex generics, and OTC products.

Employees

Sector

Pharmaceuticals

More about the company

Income Statement and Estimates

More financial data

EPS Estimates

Revisions to estimates

Quarterly revenue - Rate of surprise

Company calendar

Delayed OTC Markets Other stock markets 18:14:35 05/10/2021 +03			5-day change	1st Jan Change
4.510 ^USD	-5.65%		-2.45%	-

07-02	Cosmos Health Expands Share Buyback to 3.4 Million Shares	MT
06-30	Cosmos Health Inc. announces an Equity Buyback for $5 million worth of its shares.	CI

Market Cap	12.88M 11.26M 10.35M 9.65M 18.3M 1.23B 18.58M 124M 48.31M 603M 48.36M 47.32M 2.08B	P/E 2026 *	23.7x	P/E 2027 *	3.39x
Enterprise Value	12.88M 11.26M 10.35M 9.65M 18.3M 1.23B 18.58M 124M 48.31M 603M 48.36M 47.32M 2.08B	EV / Sales 2026 *	0.15x	EV / Sales 2027 *	0.12x
Free-Float	65.92%	Yield 2026 *	-	Yield 2027 *	-

07-02	Cosmos Health Expands Share Buyback to 3.4 Million Shares	MT
06-30	Cosmos Health Inc. announces an Equity Buyback for $5 million worth of its shares.	CI
06-30	Cosmos Health Inc. authorizes a Buyback Plan.	CI
06-26	Cosmos Health Signs Qatar Distribution Deal With IMC	MT
06-26	Cosmos Health Inc. Signs Distribution Agreement with International Medical Company, and Secures Initial Purchase Order of 31,000 Sky Premium Life Units	CI
06-23	Cosmos Health to Deploy AI-Powered Call Center at Pharma Distribution Unit	MT
06-18	Cosmos Health Inc. Expands AI Automation and Facility Capacity	CI
06-17	Cosmos Health Launches Premium Korean-Developed Collagen-Based Skincare Brand in the United States	CI
06-15	Cosmos Health Introduces Four 18 Series Products with Projected Annualized Revenue and Gross Profit in the United States	CI
06-12	Cosmos Health Gets New Contract Manufacturing Orders for 253,657 Units Across Multiple Medicines	MT
06-11	Cosmos Health Signs Letter of Intent to Buy Doc Pharma	MT
06-11	Cosmos Health Inc. has entered into a non-binding letter of intent to acquire DOC Pharma SA.	CI
06-10	Cosmos Health Unit Signs 3-Year Manufacturing Deal With Verisfield	MT

07-02	Cosmos Health Expands Buyback to 3.42 Million Shares With Additional 770,000-Share Repurchase; Continues Open Market Purchases	GL
07-01	Cosmos Health Completes Initial Repurchase of 2.65 Million Shares for $500,000; Continues Open Market Buybacks at Current Pace	GL
06-30	Cosmos Health Authorizes Up to $5 Million Share Repurchase Program	GL
06-26	Cosmos Health Signs Distribution Agreement With IMC, Owner of Qatar's Largest Pharmacy Chain; Secures Initial Purchase Order of 31,000 Sky Premium Life Units	GL
06-25	Cosmos Health Advances International Patent Application for Its Proprietary Hydrogel Weight Management Platform Across the U.S., Europe, Australia, and Canada	GL

Cosmos Holdings Inc. Stock OTC Markets

Stocks

COSM

US2214131078

Pharmaceuticals

Valuation: Cosmos Holdings Inc.

Latest news : Cosmos Holdings Inc.

Press Releases: Cosmos Holdings Inc.

News in other languages: Cosmos Holdings Inc.

Quotes and Performance

Managers and Directors: Cosmos Holdings Inc.

Pharmaceuticals Wholesale

Financials

Company Profile

Income Statement and Estimates

Quarterly revenue - Rate of surprise

29/11/24	Dalla farmaceutica al fitness: la corsa all'oro del bitcoin - Crypt On It
28/11/24	De la farmacia al gimnasio: la fiebre del bitcoin - Crypto Recap
05/12/22	Pelè non è in cure palliative - figlia
01/12/22	BASF : lance un agent nacrant naturel à base de cire

Manager	Title	Age	Since
Grigorios Siokas CEO	Chief Executive Officer	60	26/02/2016
George Terzis DFI	Director of Finance/CFO	44	11/11/2020
Nikolaos Bardakis COO	Chief Operating Officer	-	01/02/2023

Director	Title	Age	Since
Demetrios Demetriades BRD	Director/Board Member	59	13/01/2014
Grigorios Siokas CHM	Chairman	60	26/02/2016
John Hoidas BRD	Director/Board Member	60	18/11/2016

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
COSMOS HOLDINGS INC.	-5.65%	-2.45%	-	-	12.88M
MCKESSON CORPORATION	+2.37%	+2.98%	+9.31%	+86.86%	92.06B
CARDINAL HEALTH, INC.	+0.51%	+0.43%	+44.87%	+152.61%	55.96B
SIGMA HEALTHCARE LIMITED	+2.20%	+0.72%	-7.31%	+236.14%	22.26B
SHANGHAI PHARMACEUTICALS HOLDING CO., LTD	+1.26%	+5.43%	-10.09%	-24.81%	8B
HUADONG MEDICINE CO., LTD	+1.90%	+13.78%	-26.29%	-30.76%	7.76B
SINOPHARM GROUP CO. LTD.	+1.89%	+6.02%	-9.61%	-30.25%	6.66B
H. LUNDBECK A/S	-2.66%	+2.67%	+21.60%	+33.33%	6.35B
GALENICA AG	+0.17%	+0.88%	-2.65%	+21.18%	5.36B
JOINTOWN PHARMACEUTICAL GROUP CO., LTD	+1.86%	+6.93%	-5.00%	-8.21%	3.63B
Average	+0.38%	+2.75%	+1.65%	+48.45%	23.12B
Weighted average by Cap.	+1.56%	+2.45%	+14.24%	+103.10%

	2026 *	2027 *
Net sales	87.3M 76.32M 70.14M 65.37M 124M 8.31B 126M 842M 327M 4.09B 328M 321M 14.08B	111M 96.86M 89.02M 82.97M 157M 10.55B 160M 1.07B 415M 5.19B 416M 407M 17.87B
Net income	-	-
Net Debt	-	-